Candel Therapeutics, Inc. (NASDAQ:CADL – Get Rating) was the recipient of a significant drop in short interest in the month of December. As of December 30th, there was short interest totalling 30,700 shares, a drop of 39.8% from the December 15th total of 51,000 shares. Based on an average daily trading volume, of 49,300 shares, the short-interest ratio is presently 0.6 days. Approximately 0.3% of the company's shares are short sold.

Candel Therapeutics Stock Up 8.2 %

Shares of CADL traded up $0.17 during mid-day trading on Thursday, reaching $2.25. 32,302 shares of the stock traded hands, compared to its average volume of 47,250. The firm has a market cap of $65.01 million, a price-to-earnings ratio of -5.38 and a beta of 0.10. The stock has a fifty day simple moving average of $1.81 and a 200 day simple moving average of $2.61. Candel Therapeutics has a 12-month low of $1.40 and a 12-month high of $6.81. The company has a quick ratio of 13.41, a current ratio of 13.41 and a debt-to-equity ratio of 0.40.

Candel Therapeutics (NASDAQ:CADL – Get Rating) last posted its quarterly earnings data on Thursday, November 10th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.53) by $0.23. The firm had revenue of $0.03 million for the quarter. Sell-side analysts expect that Candel Therapeutics will post -1.28 EPS for the current fiscal year.

Institutional Trading of Candel Therapeutics

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Credit Suisse Group cut their price target on shares of Candel Therapeutics from $10.00 to $8.00 and set an "outperform" rating on the stock in a report on Wednesday, December 7th. HC Wainwright assumed coverage on shares of Candel Therapeutics in a report on Friday, December 2nd. They issued a "buy" rating and a $11.00 price target on the stock.

Candel Therapeutics Company Profile

(Get Rating)

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.

Read More

• Get a free copy of the StockNews.com research report on Candel Therapeutics (CADL)
• High-Dividend-Yielding BHP Sees China Driving '23 Growth
• Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
• Does a Price Cut for Tesla Vehicles Mean the Same for TSLA Stock?
• Microsoft Layoffs Signal Layoffs for Other Tech Companies?
• More Than One Reason To Buy Fastenal, Quickly

Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.